‘Acute Pain- Epidemiology Forecast-2028 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology trends of Acute Pain in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Geography Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan
Study Period: 2017-2028 Acute Pain– Disease Understanding and Treatment Algorithm Acute pain is defined as “an expected physiologic experience to injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.” The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain, basically, they are categorized into two forms, i.e., acute pain and chronic pain. Acute pain is a type of pain that typically lasts less than 3–6 months. It is of short duration but it gradually resolves as the injured tissues heal. Acute pain is distinct from chronic pain and is relatively more sharp and severe. Acute pain may be primarily caused by surgery, trauma, or other medical illness. The data on incidence and prevalence of pain, and specifically acute pain shows variety. For the assessment acute pain, various type of scaling tools are used. These scales are of two types; one dimensional and multidimensional scaling tool. The former (i.e., rating scales) usually assess a single dimension of pain, patient self-report of pain intensity. Visual Analogue Scale (VAS), Numerical Rating Scale (NRS), Faces pain scale (FPS), McGill Pain Questionnaire (MPQ) are commonly used tool to check the severity of acute pain. The Acute Pain market report gives a thorough understanding of the acute Pain by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Pain in the US, Europe, and Japan. Acute Pain – Epidemiology The acute pain epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Patient Pool with Acute Pain by Medical Condition and Severity Specific Patient Pool of Acute Pain] scenario of acute pain in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2028. epidemiology model for Acute Pain has assessed the total patient pool with Acute Pain, based on the proportion of population undergoing surgery, trauma injury and other medical illness, respectively. We have assessed that the patient pool of Acute Pool in the 7MM countries was nearly 119,619,121 cases in 2017. estimate suggests the United States showed the highest number of cases with Acute Pain, as compared to other 7MM countries. As per estimates, the country accounted for approximately 74.32% of total cases, for Acute Pain, in the 7MM countries in 2017.
As per DelevInsight’s analyst, of the population undergoing surgery in the US, nearly 80% experience acute postoperative pain, thereby contributing 41,766,061 patients to the Acute Pain population in 2017. Furthermore, among the patients with trauma injury in the US, 34,068,366 patients were contributed to the Acute Pain patient population. In contrast, the patient contribution by other acute medical illness was observed to be lowest in 2017.
Among the EU-5 countries, Germany accounted for the highest number of cases for acute pain, followed by the patient pool observed in the United Kingdom. In contrast, Spain accommodated the lowest number of cases for acute pain in this region.
Based on the severity of the disease, we have observed that patients with moderate pain accounted for the largest patient pool, followed by the number of patients with mild pain, while those with severe pain accommodated for the least patient pool. However, an overall trend was observed such that moderate-severe pain together accounted for highest patient pool in the 7MM countries.
• The report covers a descriptive overview of the Acute Pain, explaining its causes, risk factors, pathophysiology and currently available therapies. • Comprehensive insight has been provided into the epidemiology of Acute Pain in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. • Assesses growth opportunities in the 7MM countries with respect to the patient population.
• 10 Year Forecast • 7MM countries • Total Patient Pool with Acute Pain by Medical Condition • Severity Specific Patient Pool of Acute Pain
• Patient Segmentation • Disease Risk & Burden • Risk of disease by Severity
Our reports have been used by over 10K customers, including:
This Market Spotlight report covers the neuropathic pain market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue...
Overview In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totaled approximately $10.4bn. Over the forecast period covered by this analysis, total sales are expected to increase at a CAGR of 3.0%, reaching an estimated $12.1bn in 2023 This comprehensive market and medical...
Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2019 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 18 molecules. Out of which approximately 15 molecules are developed by companies...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.